Hemerion wins the Réseau Entreprendre® award
Hemerion is one of the 2020 laureates of the Réseau Entreprendre®, the first international private network of business leaders, with 126 locations worldwide, grouped in 65 associations.
Category: Timeline Stories
All timeline stories.
Hemerion wins Hodéfi award
Hemerion is one of the winners designated by Hodéfi, an association that finances and supports innovative companies in the Hauts-de-France region, and has received one of its first grants.
Therapeutic Innovation Prize
Hemerion wins the therapeutic innovation prize awarded by HDFID, an economic development and innovation agency supported by the Hauts de France Region.
Technology transfer
SATT Nord, a specialist in technology transfer from public research laboratories, grants Hemerion Therapeutics an exclusive license to exploit the anti-cancer technology co-developed by INSERM, the University of Lille and the Lille University Hospital.
Mission in Boston: Hemerion prepares its development in the United States
Hemerion has set new milestones for its international development during a 5-day mission in Boston. Read more
Hemerion raises €3.55 million to accelerate the implementation of international clinical trials for the treatment of glioblastoma
One year after the first round of funding, Hemerion’s new €3.55 million financing will accelerate the implementation of international clinical trials for the treatment of glioblastoma. Read more – Press release
Hemerion awarded the Galien MedStartup Prize
Hemerion and Mount Sinai Health System (NYC) are collaborating to launch an ambitious clinical trial in 2022. This project has won the “Best Collaboration in the MedTech and Digital Health” award of the Galien Medstartup Prize: an international recognition that perfectly kickstarts the Hemerion development in the USA. Read more – Press release
Phase II study granted authorization in Europe
Authorization granted for a phase 2 clinical trial that aims to evaluate the technology developed by Hemerion. This study is sponsored by the Lille University Hopital (France).
Hemerion gathers 1.5M€ in funding
For its preliminary funding round, Hemerion gathers 1.5M€ in dilutive and non-dilutive funding to further validate its therapeutic approach.
University of Lille Foundation awards Hemerion Therapeutics
The University of Lille’s Foundation awards the Hemerion Therapeutics founders for their scientific and entrepreuneurship involvement establishing a healthtech company.